The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Revlimid     3-(7-amino-3-oxo-1H-isoindol- 2...

Synonyms: Revamid, Revimid, Lenalidomide, IMiD3, CHEMBL848, ...
 Corral,  Blood,  Wong,  Kantarjian,  Zeldis,  Skinner,  Samuels,  Dispenzieri,  Chen,  Munshi,  Deng,  Geyer,  Hideshima,  Greipp,  Glezer,  Mueller,  Schafer,  Gertz, Wei Zhang,  Dredge,  Junkins-Hopkins,  Gandhi,  Gaspari,  Mesa,  Olesnyckyj,  Kabat,  Hussein, Cheryl Royce,  Jensen-Pergakes,  Muller,  Naziruddin,  Wu,  Clarke,  Hogan,  Strobel,  Schafer,  Harousseau,  Hussein,  Gahrton,  Lacy,  Freeman,  Brady,  Kumar,  Kang,  List,  Litzow,  Fennessey,  Byrne,  Alsina,  Mitsiades,  Oghilikhan,  Seldin, J. Paul Duic,  Verstovsek,  Richardson, Hilary Ma,  Sanchorawala,  Rajkumar, Lyndon Kim,  Sina, William D. Figg,  Warren, Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Luis Chu, Paul Musto, Ari D. Baron, Johannes C. Nunnink, Joseph J. Kash, Terenig O. Terjanian, Paul M. Hyman, Elena L. Nawfel, David J. Sharon, Nikhil C. Munshi, Kenneth C. Anderson, Paul S. Albert,  Verhelle,  Russell,  McKenney,  Weller,  Bennett,  Knight,  Harvey,  Zeldis,  Zeldenrust,  Tefferi,  Doss,  Zeldenrust,  Rosenzweig,  Chan,  Moutouh-de Parseval,  Allred,  Jagannath,  Allred,  Thomas,  Cortes,  Marriott,  Zeldis,  McClure,  Jones,  Giles,  Kelly-Colson,  Wride,  Stirling,  Hayman,  Steensma,  Dalton,  Richardson,  Muller,  Badros,  Wright,  Ketterling,  Dalgleish,  Rajkumar,  Finn,  Schlossman,  Rich,  Lopez-Girona,  Lasho,  Ferguson, Howard A. Fine,  Desikan, Tanyifor Tohnya,  Anderson,  Gorelik,  Stirling,  Lust,  Witzig,  Parton,  
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Revlimid


High impact information on Revlimid


Chemical compound and disease context of Revlimid


Biological context of Revlimid


Anatomical context of Revlimid


Associations of Revlimid with other chemical compounds


Gene context of Revlimid


Analytical, diagnostic and therapeutic context of Revlimid


  1. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., Podar, K., Le Gouill, S., Richardson, P., Munshi, N.C., Stirling, D.I., Antin, J.H., Anderson, K.C. Blood (2004) [Pubmed]
  2. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B., Gertz, M.A. Blood (2007) [Pubmed]
  3. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Sanchorawala, V., Wright, D.G., Rosenzweig, M., Finn, K.T., Fennessey, S., Zeldis, J.B., Skinner, M., Seldin, D.C. Blood (2007) [Pubmed]
  4. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R.A., Thomas, D., Lasho, T.L., Hogan, W.J., Litzow, M.R., Allred, J.B., Jones, D., Byrne, C., Zeldis, J.B., Ketterling, R.P., McClure, R.F., Giles, F., Kantarjian, H.M. Blood (2006) [Pubmed]
  5. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Fine, H.A., Kim, L., Albert, P.S., Duic, J.P., Ma, H., Zhang, W., Tohnya, T., Figg, W.D., Royce, C. Clin. Cancer Res. (2007) [Pubmed]
  6. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Chang, D.H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S.D., Jagannath, S., Dhodapkar, M.V. Blood (2006) [Pubmed]
  7. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Verhelle, D., Corral, L.G., Wong, K., Mueller, J.H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P.H., Chen, R., Glezer, E., Ferguson, G.D., Lopez-Girona, A., Muller, G.W., Brady, H.A., Chan, K.W. Cancer Res. (2007) [Pubmed]
  8. Lenalidomide: patient management strategies. Hussein, M.A. Semin. Hematol. (2005) [Pubmed]
  9. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Richardson, P. Semin. Hematol. (2005) [Pubmed]
  10. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. Palumbo, A., Rus, C., Zeldis, J.B., Rodeghiero, F., Boccadoro, M. J. Thromb. Haemost. (2006) [Pubmed]
  11. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Richardson, P., Jagannath, S., Colson, K. Clinical advances in hematology & oncology : H&O (2006) [Pubmed]
  12. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J., Anderson, K.C. Blood (2002) [Pubmed]
  13. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Zhang, H., Vakil, V., Braunstein, M., Smith, E.L., Maroney, J., Chen, L., Dai, K., Berenson, J.R., Hussain, M.M., Klueppelberg, U., Norin, A.J., Akman, H.O., Ozçelik, T., Batuman, O.A. Blood (2005) [Pubmed]
  14. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Tai, Y.T., Li, X.F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon, S.P., Grewal, I.S., Munshi, N.C., Anderson, K.C. Cancer Res. (2005) [Pubmed]
  15. The role of immunomodulatory drugs in multiple myeloma. Anderson, K.C. Semin. Hematol. (2003) [Pubmed]
  16. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Gandhi, A.K., Kang, J., Naziruddin, S., Parton, A., Schafer, P.H., Stirling, D.I. Leuk. Res. (2006) [Pubmed]
  17. The myelodysplastic syndromes: diagnosis and treatment. Steensma, D.P., Bennett, J.M. Mayo Clin. Proc. (2006) [Pubmed]
  18. Thalidomide in multiple myeloma: past, present and future. Harousseau, J.L. Future oncology (London, England) (2006) [Pubmed]
  19. Progress in hematopoietic stem cell transplantation in multiple myeloma. Gahrton, G. Curr. Opin. Hematol. (2005) [Pubmed]
  20. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Pellagatti, A., Jädersten, M., Forsblom, A.M., Cattan, H., Christensson, B., Emanuelsson, E.K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J.S., Boultwood, J., Hellström-Lindberg, E. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  21. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Treon, S.P., Soumerai, J.D., Branagan, A.R., Hunter, Z.R., Patterson, C.J., Ioakimidis, L., Chu, L., Musto, P., Baron, A.D., Nunnink, J.C., Kash, J.J., Terjanian, T.O., Hyman, P.M., Nawfel, E.L., Sharon, D.J., Munshi, N.C., Anderson, K.C. Clin. Cancer Res. (2009) [Pubmed]
  22. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Marriott, J.B., Clarke, I.A., Dredge, K., Muller, G., Stirling, D., Dalgleish, A.G. Clin. Exp. Immunol. (2002) [Pubmed]
  23. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Deng, A., Harvey, V., Sina, B., Strobel, D., Badros, A., Junkins-Hopkins, J.M., Samuels, A., Oghilikhan, M., Gaspari, A. Archives of dermatology. (2006) [Pubmed]
  24. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., Schlossman, R.L., Rajkumar, S.V., Desikan, K.R., Hideshima, T., Munshi, N.C., Kelly-Colson, K., Doss, D., McKenney, M.L., Gorelik, S., Warren, D., Freeman, A., Rich, R., Wu, A., Olesnyckyj, M., Wride, K., Dalton, W.S., Zeldis, J., Knight, R., Weller, E., Anderson, K.C. Blood (2006) [Pubmed]
  25. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Hussein, M.A. Thromb. Haemost. (2006) [Pubmed]
  26. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). List, A.F. Semin. Oncol. (2005) [Pubmed]
  27. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Barlogie, B. Semin. Hematol. (2003) [Pubmed]
WikiGenes - Universities